Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

NCT01107522 is registered in ClinicalTrials.gov with Tactical Therapeutics, Inc. as lead sponsor.

NCT NCT01107522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01107522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Lead sponsor
Tactical Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2010
Completion date
January 31, 2026
Enrollment
100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, glioblastoma, recurrent malignant gliomas